Tanabe Pharma GmbH

Clinical trials sponsored by Tanabe Pharma GmbH, explained in plain language.

Now part of Mitsubishi Chemical Group Corporation 4188 TOKYO

Pharmaceutical company focused on prescription medicines, subsidiary of Mitsubishi Tanabe Pharma.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

Heart drug safety check: does argatroban alter heart rhythms?

Knowledge-focused Completed

This completed Phase 4 study looked at whether the blood thinner argatroban causes heart rhythm changes (QTc prolongation) in 50 patients with stable coronary artery disease or unstable angina during angioplasty. Patients received argatroban by IV and had ECGs before and after th…

Phase 4 • Sponsor: Tanabe Pharma GmbH • Aim: Knowledge-focused

Last updated Jun 27, 2026 08:07 UTC

Tanabe Pharma GmbH

Heart drug safety check: does argatroban alter heart rhythms?